The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan

Abstract

The development of an HIV vaccine remains one of the most difficult challenges confronting biomedical research today. A new international collaboration shares its plan to address the challenge

Figure 1. Adults and Children Estimated to Be Living With HIV as of the End of 2004 (Total: 39.4 [35.9–44.3] million)

(Map: UNAIDS/WHO)

Figure 2. Estimated Number of Adults and Children Newly Infected with HIV during 2004 (Total: 4.9 [4.3–6.4] million)

(Map: UNAIDS/WHO)

Figure 3. Estimated Adult and Child Deaths from AIDS during 2004 (Total: 3.1 [2.8–3.5] million)

(Map: UNAIDS/WHO)

Figure 4. A Possible Model to Address Key Scientific Questions through an Appropriate Organizational Infrastructure

(Courtesy of John Mascola; illustration: Giovanni Maki)

Figure 5. A Possible Model for a Comprehensive Global Laboratory Network for the Standardized Assessment of Humoral Immune Responses

(Courtesy of David Montefiori; illustration: Giovanni Maki)

Figure 6. Proposed Organizational Structure of the Global HIV/AIDS Vaccine Enterprise (Illustration: Giovanni Maki)